In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.